Embecta Corp (EMBC)vsWest Pharmaceutical Services Inc (WST)
EMBC
Embecta Corp
$9.00
-0.11%
HEALTHCARE · Cap: $526.47M
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 185% more annual revenue ($3.07B vs $1.08B). WST leads profitability with a 16.1% profit margin vs 12.9%. EMBC trades at a lower P/E of 3.8x. EMBC earns a higher WallStSmart Score of 56/100 (C).
EMBC
Buy56
out of 100
Grade: C
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.9%
Fair Value
$110.45
Current Price
$9.00
$101.45 discount
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
EMBC profiles as a declining stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
WST is growing revenue faster at 7.5% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
EMBC scores higher overall (56/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading global medical technology firm dedicated to advancing diabetes management through its cutting-edge insulin delivery solutions. As a spin-off from Becton, Dickinson and Company, Embecta leverages innovative technologies and a comprehensive product portfolio—including insulin pens and syringes—to enhance patient care and health outcomes. Committed to operational excellence and customer-centric strategies, the company is strategically positioned to capitalize on growth opportunities in the fast-evolving diabetes care market. With a focus on improving patient experiences, Embecta aims to drive sustainable development and solidify its leadership in the industry.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?